TL;DR
This systematic review and meta-analysis found that performing diagnostic ureteroscopy (URS) before radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) significantly increases the risk of intravesical recurrence (IVR). This increased risk appears to be primarily driven by the endoscopic biopsy procedure itself, rather than URS alone, and does not negatively impact other long-term survival outcomes like cancer-specific survival or overall survival.
What Problem Does This Paper Address?
Upper tract urothelial carcinoma (UTUC) is a rare but aggressive cancer. The standard treatment for high-risk UTUC is radical nephroureterectomy (RNU), which involves removing the kidney, ureter, and a portion of the bladder. However, a significant concern after RNU is intravesical recurrence (IVR), where cancer reappears in the bladder. Some studies suggested that performing a diagnostic ureteroscopy (URS) before RNU might increase the risk of IVR, potentially due to tumor cell seeding. This paper aims to clarify this relationship by systematically reviewing and meta-analyzing existing studies to determine the impact of pre-RNU URS on IVR and other oncological outcomes.
Methods
The researchers conducted a comprehensive systematic literature search of major databases (PubMed, Embase, Cochrane Library) for studies published up to June 2021. They included retrospective studies that compared patients who underwent URS before RNU (URS+) with those who did not (URS-). The primary outcome of interest was intravesical recurrence-free survival (IVRFS), with secondary outcomes including cancer-specific survival (CSS), overall survival (OS), and metastasis-free survival (MFS). They used hazard ratios (HRs) and 95% confidence intervals (CIs) for meta-analysis, employing random-effects models where heterogeneity was significant and fixed-effects models otherwise. Exploratory subgroup analyses were performed for IVRFS to investigate the impact of factors like biopsy status, URS technique, and tumor location.
Datasets
This study is a systematic review and meta-analysis, meaning it analyzes data from previously published studies. It does not introduce new datasets or benchmarks. The data for the meta-analysis were extracted from sixteen selected retrospective studies, encompassing a total of 5489 patients.
Key Insights and Ideas
- Biopsy is the Culprit, Not URS Alone: The most striking finding is that the increased risk of IVR is strongly linked to performing an endoscopic biopsy during URS, not simply the act of diagnostic ureteroscopy itself. Patients who underwent URS without biopsy showed similar IVRFS rates to those who had no URS at all.
- No Impact on Long-Term Survival: While IVRFS is negatively affected, the study found no significant impact of pre-RNU URS on other crucial oncological outcomes like cancer-specific survival, overall survival, or metastasis-free survival. This suggests that while recurrence in the bladder is more likely, it doesn't necessarily translate to worse overall prognosis.
- Tumor Location Matters: Exploratory analyses indicated that the increased IVR risk associated with URS biopsy might be more pronounced in patients with renal pelvic tumors compared to ureteral tumors. This suggests a potential need for tailored approaches based on tumor location.
- Bladder Cancer History Doesn't Worsen Risk: Interestingly, patients with a history of bladder cancer who underwent URS before RNU did not show a worse IVRFS compared to those without such a history.
Key Results
- Increased IVR Risk: Diagnostic URS prior to RNU was significantly associated with worse IVRFS (HR = 1.44, 95% CI: 1.29–1.61, p < 0.001).
- Biopsy-Specific Risk: When URS was performed without biopsy, the impact on IVRFS was not significant (HR = 1.28, 95% CI: 0.90–1.80, p = 0.16). However, when URS with biopsy was performed, the risk was significantly higher.
- No Impact on Other Survival Outcomes: No significant differences were found in CSS (HR = 0.94, p = 0.63), OS (HR: 0.94, p = 0.56), and MFS (HR: 0.91, p = 0.37) between the URS+ and URS- groups.
- Subgroup Analysis: Patients with a history of bladder tumors did not show a worse IVRFS when undergoing URS before RNU (HR = 1.71, 95% CI: 1.48-1.97, p < 0.001).
Limitations and Future Work
The authors acknowledge several limitations. Primarily, all included studies were retrospective, which inherently carries risks of selection bias and confounding. The adjustments for confounders in the statistical analyses were not uniform across studies, and some relied on univariable data. Data on specific URS techniques (rigid vs. flexible) and urine cytology during URS were not consistently reported, limiting the ability to fully explore their impact. Furthermore, subgroup analyses were sometimes based on a limited number of patients.
The authors suggest that future studies should focus on the role of immediate postoperative intravesical chemotherapy, particularly in patients undergoing biopsy during URS for suspected UTUC. This could potentially mitigate the increased IVR risk observed. They also highlight the need for more robust prospective studies to confirm these findings and to better understand the nuances of URS use in UTUC management.
Summary updated